• Rohit A Gupta, James P Higham, Abigail Pearce, Paulina Urriola-Muñoz, Katie H Barker, Luke Paine, Joshua Ghooraroo, Tim Raine, HockleyJames R FJRFDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, United Kingdom., Taufiq Rahman, St John SmithEwanEDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, United Kingdom., Alastair J H Brown, Graham Ladds, Rie Suzuki, and David C Bulmer.
• Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, United Kingdom.
• Pain. 2024 Oct 3.

AbstractThe development of nonopioid analgesics for the treatment of abdominal pain is a pressing clinical problem. To address this, we examined the expression of Gi/o-coupled receptors, which typically inhibit nociceptor activation, in colonic sensory neurons. This led to the identification of the orphan receptor GPR35 as a visceral analgesic drug target because of its marked coexpression with transient receptor potential ankyrin 1 (TRPA1), a mediator of noxious mechanotransduction in the bowel. Building on in silico docking simulations, we confirmed that the mast cell stabiliser, cromolyn (CS), and phosphodiesterase inhibitor, zaprinast, are agonists at mouse GPR35, promoting the activation of different Gi/o subunits. Pretreatment with either CS or zaprinast significantly attenuated TRPA1-mediated colonic nociceptor activation and prevented TRPA1-mediated mechanosensitisation. These effects were lost in tissue from GPR35-/- mice and were shown to be mediated by inhibition of TRPA1-evoked substance P (SP) release. This observation highlights the pronociceptive effect of SP and its contribution to TRPA1-mediated colonic nociceptor activation and sensitisation. Consistent with this mechanism of action, we confirmed that TRPA1-mediated colonic contractions evoked by SP release were abolished by CS pretreatment in a GPR35-dependent manner. Our data demonstrate that GPR35 agonists prevent the activation and sensitisation of colonic nociceptors through the inhibition of TRPA1-mediated SP release. These findings highlight the potential of GPR35 agonists to deliver nonopioid analgesia for the treatment of abdominal pain.Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain.

20 keywords...

hide…